The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...

According to a study, presented during the ongoing European Congress on Obesity in Spain, on direct comparison between the two, Zepbound helped people lose more weight and more belly fat, reported ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent trial. The study enhances Lilly's position in the obesity drug market, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...